Iovance Biotherapeutics Inc
Research Iovance Biotherapeutics Inc (IOVA) on Bullrun: market cap USD 3.82B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerIOVA
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 3.82B
- Financial periodQ2 2026
- RevenueUSD 99.31M
- Net income-USD 47.32M
- Free cash flow-USD 66.28M
- Gross margin56.1%
Valuation Snapshot
latest market cap is USD 3.82B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 263.50M | -USD 391.00M | -USD 336.24M | 34.3% | -1.09 | USD 163.08M | USD 49.44M | USD 698.58M |
| FY2024 | USD 164.07M | -USD 372.20M | -USD 364.05M | 43.2% | -1.28 | USD 115.69M | USD 58.26M | USD 710.41M |
| FY2023 | USD 1.19M | -USD 444.00M | -USD 384.11M | 13.1% | -1.89 | USD 114.89M | USD 75.86M | USD 584.61M |
| FY2022 | n/a | -USD 395.90M | -USD 313.18M | n/a | -2.49 | USD 231.73M | USD 80.48M | USD 499.64M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 3.82B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.12B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 2.26B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 2.08B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 1.01B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 3.00B | n/a | n/a | n/a |
About Iovance Biotherapeutics Inc
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Iovance Biotherapeutics Inc's market cap?
Iovance Biotherapeutics Inc's market capitalization is USD 3.82B.
What does Iovance Biotherapeutics Inc do?
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally.